PBPK Model Describes the Effects of Comedication and Genetic Polymorphism on Systemic Exposure of Drugs That Undergo Multiple Clearance Pathways

An important goal in drug development is to understand the effects of intrinsic and/or extrinsic factors (IEFs) on drug pharmacokinetics. Although clinical studies investigating a given IEF can accomplish this goal, they may not be feasible for all IEFs or for situations when multiple IEFs exist concurrently. Physiologically based pharmacokinetic (PBPK) models may serve as a complementary tool for forecasting the effects of IEFs. We developed PBPK models for four drugs that are eliminated by both cytochrome P450 (CYP)3A4 and CYP2D6, and evaluated model prediction of the effects of comedications and/or genetic polymorphism on drug exposure. PBPK models predicted 100 and ≥70% of the observed results when the conventional “twofold rule” and the more conservative 25% deviation cut point were applied, respectively. These findings suggest that PBPK models can be used to infer effects of individual or combined IEFs and should be considered to optimize studies that evaluate these factors, specifically drug interactions and genetic polymorphism of drug‐metabolizing enzymes.

[1]  J. Azuma,et al.  The relationship between clinical pharmacokinetics of aripiprazole and CYP2D6 genetic polymorphism: effects of CYP enzyme inhibition by coadministration of paroxetine or fluvoxamine , 2011, European Journal of Clinical Pharmacology.

[2]  Alex Phipps,et al.  Comparison of Different Algorithms for Predicting Clinical Drug-Drug Interactions, Based on the Use of CYP3A4 in Vitro Data: Predictions of Compounds as Precipitants of Interaction , 2009, Drug Metabolism and Disposition.

[3]  C. Eap,et al.  The effect of fluoxetine on the pharmacokinetics and safety of risperidone in psychotic patients. , 2002, Pharmacopsychiatry.

[4]  Tudor I. Oprea,et al.  BDDCS Applied to Over 900 Drugs , 2011, The AAPS Journal.

[5]  S. Sriwiriyajan,et al.  Effect of cytochrome P450 3A4 inhibitor ketoconazole on risperidone pharmacokinetics in healthy volunteers , 2012, Journal of clinical pharmacy and therapeutics.

[6]  S. Hall,et al.  Prediction of cytochrome P450 3A inhibition by verapamil enantiomers and their metabolites. , 2004, Drug metabolism and disposition: the biological fate of chemicals.

[7]  A. Galetin,et al.  Quinidine and haloperidol as modifiers of CYP3A4 activity: multisite kinetic model approach. , 2002, Drug metabolism and disposition: the biological fate of chemicals.

[8]  Critique of the Two-Fold Measure of Prediction Success for Ratios: Application for the Assessment of Drug-Drug Interactions , 2011, Drug Metabolism and Disposition.

[9]  J S Harmatz,et al.  Triazolam biotransformation by human liver microsomes in vitro: effects of metabolic inhibitors and clinical confirmation of a predicted interaction with ketoconazole. , 1996, The Journal of pharmacology and experimental therapeutics.

[10]  Shufeng Zhou.  Polymorphism of Human Cytochrome P450 2D6 and Its Clinical Significance , 2009, Clinical pharmacokinetics.

[11]  V. Roongta,et al.  Inhibitory Effect of Ketoconazole on the Pharmacokinetics of a Multireceptor Tyrosine Kinase Inhibitor BMS‐690514 in Healthy Participants: Assessing the Mechanism of the Interaction With Physiologically‐Based Pharmacokinetic Simulations , 2013, Journal of clinical pharmacology.

[12]  Malcolm Rowland,et al.  Physiologically-based pharmacokinetics in drug development and regulatory science. , 2011, Annual review of pharmacology and toxicology.

[13]  J. Azuma,et al.  Influence of itraconazole co-administration and CYP2D6 genotype on the pharmacokinetics of the new antipsychotic ARIPIPRAZOLE. , 2005, Drug metabolism and pharmacokinetics.

[14]  Jennifer L. Donovan,et al.  Comparative CYP3A4 Inhibitory Effects of Venlafaxine, Fluoxetine, Sertraline, and Nefazodone in Healthy Volunteers , 2004, Journal of clinical psychopharmacology.

[15]  Louise Poissant.  Part I , 1996, Leonardo.

[16]  L Zhang,et al.  Predicting Drug Interaction Potential With a Physiologically Based Pharmacokinetic Model: A Case Study of Telithromycin, a Time‐Dependent CYP3A Inhibitor , 2012, Clinical pharmacology and therapeutics.

[17]  Shiew-Mei Huang,et al.  The utility of modeling and simulation in drug development and regulatory review. , 2013, Journal of pharmaceutical sciences.

[18]  T. Gomes,et al.  Macrolide‐Induced Digoxin Toxicity: A Population‐Based Study , 2009, Clinical pharmacology and therapeutics.

[19]  W. Trager,et al.  Comparison of in vitro and in vivo inhibition potencies of fluvoxamine toward CYP2C19. , 2003, Drug metabolism and disposition: the biological fate of chemicals.

[20]  G. Yee,et al.  Pharmacokinetic Drug Interactions with Cyclosporin (Part II) , 1990, Clinical pharmacokinetics.

[21]  M. Dickins,et al.  Effects of the moderate CYP3A4 inhibitor, fluconazole, on the pharmacokinetics of fesoterodine in healthy subjects. , 2011, British journal of clinical pharmacology.

[22]  Alex Phipps,et al.  Application of CYP3A4 in vitro data to predict clinical drug-drug interactions; predictions of compounds as objects of interaction. , 2008, British journal of clinical pharmacology.

[23]  D. Greenblatt,et al.  Inhibition of alprazolam and desipramine hydroxylation in vitro by paroxetine and fluvoxamine: comparison with other selective serotonin reuptake inhibitor antidepressants. , 1995, Journal of clinical psychopharmacology.

[24]  J Snoeys,et al.  Evaluation of Various Static In Vitro–In Vivo Extrapolation Models for Risk Assessment of the CYP3A Inhibition Potential of an Investigational Drug , 2014, Clinical pharmacology and therapeutics.

[25]  Michael Gertz,et al.  Physiologically Based Pharmacokinetic Modeling of Intestinal First-Pass Metabolism of CYP3A Substrates with High Intestinal Extraction , 2011, Drug Metabolism and Disposition.

[26]  鮫島 浩,et al.  Population-based study からみた神経予後不良因子の検討 , 2009 .

[27]  Ping Zhao,et al.  A Physiologically Based Pharmacokinetic Model to Predict Disposition of CYP2D6 and CYP1A2 Metabolized Drugs in Pregnant Women , 2013, Drug Metabolism and Disposition.

[28]  Ying-Hong Wang,et al.  Confidence Assessment of the Simcyp Time-Based Approach and a Static Mathematical Model in Predicting Clinical Drug-Drug Interactions for Mechanism-Based CYP3A Inhibitors , 2010, Drug Metabolism and Disposition.

[29]  M Rowland,et al.  Best Practice in the Use of Physiologically Based Pharmacokinetic Modeling and Simulation to Address Clinical Pharmacology Regulatory Questions , 2012, Clinical pharmacology and therapeutics.

[30]  L Zhang,et al.  Applications of Physiologically Based Pharmacokinetic (PBPK) Modeling and Simulation During Regulatory Review , 2011, Clinical pharmacology and therapeutics.

[31]  A. Altamura,et al.  Clinical Pharmacokinetics of Fluoxetine , 1994, Clinical pharmacokinetics.

[32]  L. Ereshefsky,et al.  Pharmacokinetic and Pharmacodynamic Interactions of Oral Midazolam with Ketoconazole, Fluoxetine, Fluvoxamine, and Nefazodone , 2003, Journal of clinical pharmacology.

[33]  P. Glue,et al.  Comparison of pharmacokinetic variability of fesoterodine vs. tolterodine extended release in cytochrome P450 2D6 extensive and poor metabolizers. , 2011, British journal of clinical pharmacology.

[34]  R. Bergstrom,et al.  Quantification and mechanism of the fluoxetine and tricyclic antidepressant interaction , 1992, Clinical pharmacology and therapeutics.

[35]  R. Reeves,et al.  Evaluation of the Pharmacokinetic and Pharmacodynamic Interaction Between Quinidine and Nifedipine , 1993, Journal of clinical pharmacology.

[36]  J. Fleishaker,et al.  A pharmacokinetic and pharmacodynamic evaluation of the combined administration of alprazolam and fluvoxamine , 2004, European Journal of Clinical Pharmacology.

[37]  G. Yee,et al.  Pharmacokinetic Drug Interactions with Cyclosporin (Part I) , 1990, Clinical pharmacokinetics.